Post-earnings recap
Reported
Thu, May 5, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss per share of $0.35, which was slightly worse than expected. The stock reacted negatively, dropping 8.88% following the earnings report. Investors may be concerned about the lack of revenue updates and the company's financial outlook moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.35 | N/A | -1.74% |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their clinical pipeline. However, they did not provide any updates on future revenue expectations.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on advancing its clinical programs despite the current financial results.